Show Summary Details
Page of

Pharmacogenetics of Late-Life Depression 

Pharmacogenetics of Late-Life Depression
Pharmacogenetics of Late-Life Depression

Greer M. Murphy

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 19 January 2022

There have been relatively few studies on pharmacogenetic predictors of antidepressant response in the elderly. The focus has been primarily on either pharmacokinetic markers such as CYP2D6 polymorphisms that affect drug levels, or pharmacodynamic markers such as serotonin receptor and transporter polymorphisms that influence drug interactions with neurons. So far, nothing of demonstrated clinical value has emerged from these investigations of antidepressant pharmacogenetics in late-life depression. Psychiatric pharmacogenetics is handicapped by small sample sizes, lack of replication studies, and problems in study design. Many of these difficulties are shared with the broader pharmacogenetics field as a whole. However, with further research the potential exists to identify genetic markers that could guide prescribing of antidepressants specifically in the elderly population.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.